Our R&D approach is grounded in a thoughtful focus on real-world challenges faced by people living with complex and serious diseases. Through this lens, we seek to develop innovative medicines in neuroscience and oncology that can bring value to patients.
Our scientists are focused on developing new molecules that leverage well-validated biological pathways, utilizing our expertise in advanced medicinal chemistry and protein engineering, coupled with a disciplined, integrated research approach.
ALKS 3831* - Schizophrenia/Bipolar I Disorder
ALKS 1140 - Neurology (Orphan)
Orexin 2 Receptor Agonist - Narcolepsy
HDAC Inhibitors - Neurology/Neuropsychiatry (Non-Orphan)
HDAC Inhibitors - Frontotemporal Dementia
Tumor-Targeted Split IL-12
Our synaptic dysfunction platform is designed to improve the structure, function and environment of synapses. Improvement of synaptic integrity and function has the potential to slow progression, and preserve cognitive and functional abilities, in multiple neurological and psychiatric diseases.
Our immuno-oncology platform is designed to harness the power of the immune system to fight cancer. We are developing novel cytokine-based therapies designed to increase visibility of tumor cells to the immune system, increase the tumor-killing potential of CD8+ T and Natural Killer cells, and remove suppressive signals in the tumor microenvironment. Nemvaleukin alfa, our most advanced investigational immunotherapy candidate, was developed using this platform.
Our suite of long-acting injectable technologies enables the gradual release of small molecules as well as complex macromolecules into the body at a controlled rate over a specific period of time. These include Medisorb®, LinkeRx® and NanoCrystal®.
Our broad array of customized, solid-oral dosage technologies, including oral delayed-release, extended-release, immediate-release, pulsatile-release and chrono-timed delivery enable us to customize specific drug-release profiles and dosage forms.
We are harnessing our established protein engineering platforms to develop novel cytokines with the potential to fight cancer.
We have built a sophisticated molecular design toolbox to support our small molecule and biologics projects. This includes advanced molecular dynamics simulations, quantum chemical calculations, artificial intelligence and proprietary machine learning models.
We seek to support investigator research designed and conducted by independent clinicians and scientists. Since the onset of our Investigator Sponsored Studies (ISS) program in 2008, we have supported more than 40 clinical trials.
Alkermes Pathways Research Awards® is a competitive grant program for early-career investigators working on the front lines to advance understanding and awareness of disease states in the field of neuroscience.
We contribute to independent education by supporting medical education grants. Our focus areas include accredited educational activities with pragmatic approaches to improve patient care and public health in the areas of schizophrenia, bipolar disorder, opioid use disorder and alcohol use disorder.